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Abstract
Background: The clinical course of cystic fibrosis (CF) is characterized by recurrent pulmonary
infections and chronic inflammation. We have recently shown that decreased methylation of the
toll-like receptor-2 (TLR2) promoter leads to an apparent CF-related up-regulation of TLR2. This
up-regulation could be responsible, in part, for the CF-associated enhanced proinflammatory
responses to various bacterial products in epithelial cells. However, the molecular mechanisms
underlying DNA hypomethylation-dependent enhancement of TLR2 expression in CF cells remain
unknown.
Results: The present study indicates that there is a specific CpG region (CpG#18-20), adjacent to
the SP1 binding site that is significantly hypomethylated in several CF epithelial cell lines. These
CpGs encompass a minimal promoter region required for basal TLR2 expression, and suggests that
CpG#18-20 methylation regulates TLR2 expression in epithelial cells. Furthermore, reporter gene
analysis indicated that the SP1 binding site is involved in the methylation-dependent regulation of
the TLR2 promoter. Inhibition of SP1 with mithramycin A decreased TLR2 expression in both CF
and 5-azacytidine-treated non-CF epithelial cells. Moreover, even though SP1 binding was not
affected by CpG methylation, SP1-dependent transcription was abolished by CpG methylation.
Conclusion: This report implicates SP1 as a critical component of DNA demethylation-dependent
up-regulation of TLR2 expression in CF epithelial cells.
Background
The innate immune system recognizes conserved micro-
bial products, termed pathogen-associated molecular pat-
terns (PAMPs), that are invariant among diverse groups of
microorganisms. PAMPs are recognized by a set of germ-
line encoded pattern recognition receptors (PRRs) includ-
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ing toll-like receptors (TLRs) [1-3]. After the recognition
of microbial PAMPs by innate immune systems, TLRs acti-
vate signaling pathways that induce inflammatory
cytokines and antimicrobial peptides to eliminate invad-
ing pathogens. Eleven members of the mammalian TLR
family have been identified and cloned thus far. TLR2 and
TLR4 have been studied in the greatest depth [4,5], and
TLR4 appears to be primarily involved in the recognition
of lipopolysaccharide (LPS) from Gram-negative bacteria
[5]. In contrast, TLR2 responds to a variety of both Gram-
negative and Gram-positive bacterial products, including
peptidoglycan, lipoprotein, lipoteichoic acid, and lipoara-
binomannan. This suggests that TLR2 plays a critical role
in the host defence system [4].
TLR2 is primarily expressed in monocytes, macrophages,
dendritic cells, and granulocytes. There is also a growing
body of evidence indicating that TLR2 is inducibly
expressed in epithelial tissues. Previous studies have
shown that TLR2 is expressed at a low level in human epi-
thelial cells under physiological conditions. However,
TLR2 expression is greatly increased during bacterial infec-
tions through an NF-?B-dependent mechanism [6,7].
Inducible expression of human TLR2 by the proinflam-
matory cytokine, TNF?, was also indicated in lung Type II-
like A549 epithelial cells [8]. These findings indicate that
increased TLR2 expression during bacterial infection may
contribute in accelerating the immune response to invad-
ing pathogens.
Although optimal TLR2 signaling is required to activate
epithelial cells against microorganisms, excessive or inap-
propriate TLR2 expression and signaling could contribute
to hyperresponsiveness against bacterial ligands, and
enhance the inflammatory responses frequently detri-
mental to the host [6,9-12]. Our previous studies indicate
that expression of TLR2 is higher in the airway mucosae of
chronic otitis media patients than in normal subjects [6],
and is also associated with inflammatory bowel disease
(IBD) such as Crohn's disease [11,12]. These reports
implicate hyperresponsiveness to bacterial infection as a
cause of the enhanced susceptibility to chronic inflamma-
tion. Thus, regulation of TLR2 expression is likely an
important immune-regulatory mechanism, commonly
involved in host defence against bacterial infections.
The clinical course of cystic fibrosis (CF), the most com-
mon lethal inherited disorder in Caucasians, is character-
ized by two major respiratory symptoms, recurrent
pulmonary infection and chronic inflammation that ulti-
mately lead to death from respiratory failure [13,14]. Two
previous studies [15,16] showed a modest up-regulation
of TLR2 in CF airway epithelial cells that is consistent with
an increased proinflammatory response to TLR2-activat-
ing bacterial ligands found in CF airways. In accordance
with these findings, an increase in the expression of TLR2
gene in CF epithelial cells due to the hypomethylation of
the TLR2 promoter has been demonstrated [17]. How-
ever, the molecular mechanisms underlying this
hypomethylation-dependent activation of TLR2 transcrip-
tion in human CF epithelial cells remain unknown.
The present study shows that a specific CpG region, adja-
cent to an SP1 binding site, are hypomethylated in CF epi-
thelial cells. The minimal region required for
maintenance of basal TLR2 promoter activity was com-
prised of the CpG site adjacent to an SP1 binding site. Fur-
thermore, SP1-dependent transcriptional activity, but not
SP1 binding, was shown to be elevated in the hypometh-
ylation-dependent enhancement of TLR2 gene expression
in CF epithelial cells.
Results
Identification of CF-specific methylation patterns within 
the human TLR2 promoter
We recently showed that decreased methylation of human
TLR2 (hTLR2) promoter is responsible for enhanced TLR2
expression in CF epithelial cells, and suggested that this
increased TLR2 expression is responsible for augmenting
the proinflammatory response to various bacterial prod-
ucts [17]. To identify specific promoter regions among the
20 potentially hypomethylated CpG sites in CF epithelial
cells, the methylation profiles of these sites were charac-
terized by bisulfite sequence analysis. The 20 CpG sites
(Fig. 1) were first bundled together into eight groups
based on the relative proximity of each CpG (Table 2).
The methylation status of these eight CpG groupings was
then analyzed in non-CF (16HBE14o-, HeLa, A549) and
CF (CFBE41o-, CFTE29o-, CFPAC-1) epithelial cells. The
proportion of methylated to unmethylated sites was
assessed. Statistical analysis using Fischer's exact test com-
pared non-CF/CF cells in the context of methylated/
unmethylated CpGs in each site (Table 2). This analysis
identified CpG groupings #1–3 and #18–20 as signifi-
cantly hypomethylated (p < 0.001) and CpG groupings
#6–8, #13–15 and #16–17 as moderately hypomethyl-
ated (p < 0.05). Statistical analysis showed that the meth-
ylation of CpG groupings #4–5, #9–10 and #11–12 were
not significantly different (p > 0.05) between non-CF and
CF epithelial cells. These findings suggest that there are
CF-specific methylation patterns (CFSMPs) within the
TLR2 promoter that may play a role in CF pathology.
Identification of the minimal promoter region required for 
basal TLR2 promoter activity in human epithelial cells
Assessment of a possible correlation between CFSMPs
within the TLR2 promoter and a minimal TLR2 promoter
region required for basal TLR2 promoter activity was per-
formed by deletion analysis of the TLR2 promoter. A
series of reporter plasmids containing various lengths ofBMC Molecular Biology 2008, 9:39 http://www.biomedcentral.com/1471-2199/9/39
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the promoter region were constructed (Fig. 2A). These
constructs were transfected into non-CF (16HBE14o-,
HeLa, A549) and CF (CFBE41o-, CFTE29o-, CFPAC-1)
epithelial cells. The CF cells express high levels of TLR2,
while the non-CF cells express low levels of TLR2 mRNA
(Fig. 2A, RT-PCR). Luciferase activity in all cell lines
decreased as a function of promoter length (i.e., transfec-
tion with plasmids pGL3-T2P (-120) through pGL3-T2P (-
12)) (Fig 2A), indicating that there are primary promoter
regulatory elements between -120- to -12-bp upstream of
the TLR2 gene coding sequences. We noted that the pat-
tern of luciferase activity for the different constructs in the
non-CF cells seemed to be similar to the pattern of activity
measured in the CF epithelial cells even though the non-
CF epithelial cells show very low levels of endogenous
TLR2 mRNA expression (Fig. 2A). Statistical analysis
showed that the differences between non-CF and CF epi-
thelial cells in promoter activity of the reporter constructs
were not significant (Student's t-test, p > 0.05) (Fig. 2B).
This was not an unexpected result because the TLR2 pro-
moter sequences in CF and non-CF cells are identical.
To further restrict a minimal region required for TLR2
basal promoter activity, we constructed pGL3-T2P (-60)
Schematic representation of the human TLR2 promoter Figure 1
Schematic representation of the human TLR2 promoter. Binding sites for different transcription factors are indicated. 
Black lines are CpG sites that can be methylated. Transcriptional start site is indicated as +1.
18 1
 
92 0
-
 
1
 
2 -
 
1
 
2
 
0 -194 -
 
3
 
0
 
9 +
 
1
S
 
P
 
1
N
 
F
 
-κ κ κ κB
E
 
T
 
S 34 5 6 7 89 1 0 1
 
11
 
21
 
31
 
41
 
51
 
61
 
7 12
C
 
p
 
G
 
#
-60
Table 1: Oligonucleotides used for this study
Primers used for the generation of TLR2 promoter/reporter constructs
pGL3-T2P(-309) 5'-GCCTCTAGCGTCTCGATTCGC-3' 5'-CTGGGAGAACTCCGAGCAGTC-3'
pGL3-T2P(-194) 5'-CTGTCGCAGCCTAGCTCACGG-3' 5'-CTGGGAGAACTCCGAGCAGTC-3'
pGL3-T2P(-120) 5'-CCTGCCTGGAACTCAGCGCG-3' 5'-CTGGGAGAACTCCGAGCAGTC-3'
pGL3-T2P(-60) 5'-TGCCCCGTGGAAGGGGCGGTT-3' 5'-CTGGGAGAACTCCGAGCAGTC-3'
pGL3-T2P(-12) 5'-CGCGCGGACTTTCCCTTTTGC-3' 5'-CTGGGAGAACTCCGAGCAGTC-3'
Primers used for the generation of mutant TLR2 promoter/reporter constructsa
pGL3-T2P(-120) SPm 5'-CCCGTGGAAGGTTAGGTTCCCGCACCCCAG-3' 5'-CTGGGGTGCGGGAACCTAACCTTCCACGGG-3'
pGL3-T2P(-120)/(-60) ETSm 5'-GCGCACGTGCCCCGACGAAGGGGCGGTTCC-3' 5'-GGAACCGCCCCTTCGTCGGGGCACGTGCGC-3'
Primers used for semi-quantitative RT-PCR
SP1 5'-TGTGAATGCTGCTCAACTCTCC-3' 5'- CATGTATTCCATCACCACCAG -3'
SP3 5'-AACCTGATCCTGAAGAGTGGC-3' 5'-TGGCGGAAGTATTAACAGTTCC-3'
Oligonucleotides used for EMSAb
T2P(-64/-31) 5'-GTGCCCCGTGGAAGGGGCGGTTCCCGCACCCCAG-3' 5'-CTGGGGTGCGGGAACCGCCCCTTCCACGGGGCAC-3'
T2P(-64/-31) SPm 5'-GTGCCCCGTGGAAGGTTAGGTTCCCGCACCCCAG-3' 5'-CTGGGGTGCGGGAACCTAACCTTCCACGGGGCAC-3'
T2P(-64/-31)-monoMe 5'-GTGCCCCGTGGAAGGGGCGGTTCCCGCACCCCAG-3' 5'-CTGGGGTGCGGGAAC/M-C/GCCCCTTCCACGGGGCAC-3'
T2P(-64/-31)-triMe 5'-GTGCCCCGTGGAAGGGGCGGTTCCCGCACCCCAG-3' 5'-CTGGGGTG/M-C/GGGAAC/M-C/GCCCCTTCCA/M-C/GGGGCAC-3'
a Mutations introduced in the oligonucleotides are shown in italic.
b Putative SP1 binding sequences are underlined. Mutations introduced in the oligonucleotides are shown in italic. M-C represents methylated cytosine.BMC Molecular Biology 2008, 9:39 http://www.biomedcentral.com/1471-2199/9/39
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plasmid. This construct contains only one E26 transform-
ing-specific (ETS) site and one SP1 binding site (Fig. 2C).
The luciferase activity in the cells transfected with pGL3-
T2P (-60) was 3-fold higher than in those transfected with
pGL3-T2P (-12), indicating that the minimal promoter is
located between -60-bp to -12-bp upstream of the tran-
scription start site (Fig. 2C). It is important to note that
this minimal region comprises CpG#18-20, and is signif-
icantly hypomethylated in CF epithelial cells. These find-
ings support the notion that this region regulates TLR2
expression.
SP1 binding site adjacent to CpG#18-20 in human 
epithelial cells
Since CpG#18-20 is located adjacent to putative SP1 and
ETS binding sites (Fig. 1), binding to these sites was
assessed to determine whether they were required for
minimal promoter activity. Mutations were introduced
into the SP1 and ETS binding sites in the reporter plas-
mids. The introduction of a SP1 mutation into the pGL3-
T2P (-120) plasmid reduced the basal TLR2 promoter
activity in both non-CF and CF epithelial cells (Fig 3A),
indicating that this SP1 binding site is involved in modu-
lating TLR2 basal promoter activity. On the other hand, a
mutation in the ETS binding site in either the pGL3-T2P (-
120) or in the pGL3-T2P (-60) construct did not affect
TLR2 promoter activity (Fig. 3B and 3C).
Regulation of TLR2 promoter activity and its gene 
expression by SP1
SP1 binding adjacent to CpG#18-20 appears to be critical
for basal TLR2 transcription, so to test the extent to which
SP1 regulates TLR2 transcription, cells were treated with
mithramycin A (mitA), a known Sp1-binding inhibitor
[18]. Treatment of HeLa cells with mitA reduced basal
TLR2 promoter activity in a dose-dependent manner (Fig.
4A, pGL3-T2P (-120) + pcDNA3.1). Furthermore, trans-
fection of the cells with an SP1 expression vector caused a
four-fold increase in basal TLR2 promoter activity that
could be suppressed by mitA (Fig. 4A, pGL3-T2P (-120) +
SP1). HeLa cells transfected with a plasmid, pGL3P (-120)
SPm that contained a mutant SP1 binding site showed a
significant reduction in SP1-induced promoter activity
(Fig. 4B, p < 0.0001). MitA treatment of CFBE41o- cells
suppressed the intrinsic TLR2 mRNA expression in a dose-
dependent manner (Fig. 4C). SP3 had no effect on the
basal TLR2 promoter activity (Fig. 4A, pGL3-T2P (-120) +
SP3). These results indicate that SP1, but not SP3, up-reg-
ulates TLR2 promoter activity and gene expression.
Inhibition of basal and SP1-induced TLR2 promoter 
activity by in vitro DNA methylation
The effect of in vitro DNA methylation on the promoter
activity of human TLR2 gene was investigated through
transient transfection of HeLa cells with methylated CpG
reporter constructs. Endogenously activated luciferase
activity was significantly reduced in the cells transfected
with the methylated pGL3-T2P (-120) construct and an
empty expression vector (pGL3-T2P (-120) + pcDNA3.1)
(Fig. 5). Moreover, when cells were transfected with the
methylated pGL3-T2P (-120) and a vector expressing SP1,
TLR2 promoter activity was significantly inhibited (Fig. 5,
pGL3-T2P (-120) + SP1), indicating that SP1-mediated
transcriptional activation was inhibited by promoter CpG
methylation.
Table 2: Methylation of CpG sites in the TLR2 promoter is significantly different between non-CF and CF epithelial cellsa
CpG# Sequences Methylated Unmethylated p values
#1–3 non-CF 43 46 83
CF 41 17 106 7.277 × 10-5***
#4–5 non-CF 43 18 68
CF 41 22 60 0.4698
#6–8 non-CF 43 8 121
CF 41 1 122 0.0362*
#9–10 non-CF 43 3 83
CF 41 1 81 0.6209
#11–12 non-CF 43 6 80
CF 41 1 81 0.1179
#13–15 non-CF 43 20 109
CF 41 8 115 0.0273*
#16–17 non-CF 43 12 74
CF 41 3 79 0.0282*
#18–20 non-CF 43 22 107
CF 41 4 119 0.0003***
aCpG methylation was scored at specific sites (CpG#1-3, 4–5, 6–8, 9–10, 1–12, 13–15, 16–17 and 18–20) in the TLR2 promoter sequence from 
non-CF (16HBE14o-, n = 23; HeLa, n = 10; A549, n = 10) and CF (CFBE41o-, n = 21; CFTE41o-, n = 10; CFPAC-1, n = 10) epithelial cells. The 
number of methylated and unmethylated sites was scored and a Fischer's exact test was used to assign p values (*, p < 0.05; ***, p < 0.001).BMC Molecular Biology 2008, 9:39 http://www.biomedcentral.com/1471-2199/9/39
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Minimal region necessary for basal TLR2 promoter activity overlaps with the CpG sites adjacent to SP1 (CpG#18-20) Figure 2
Minimal region necessary for basal TLR2 promoter activity overlaps with the CpG sites adjacent to SP1 (CpG#18-20). (A) Deletion anal-
ysis of human TLR2 5'-regulatory CpG-rich region. 5'-serial deletion reporter constructs were transiently transfected into non-CF and CF epithelial cells. 
Luciferase activity is expressed as percent of the activity of pGL3-T2P (-309). Bar graphs represent the mean ± S.E.M. from 3 independent experiments 
performed in triplicate. TLR2 mRNA expression levels of each cell line are shown. (B) Comparison of non-CF and CF epithelial cell promoter activity in 
each deletion construct. Each data point represents luciferase activity in non-CF (16HBE14o-, HeLa, A549) and in CF (CFBE41o-, CFTE29o-, CFPAC-1) 
epithelial cells (n = 3 for each cell line). Mean values are represented as grey bar. The difference between non-CF and CF epithelial cells in promoter activ-
ity for each reporter construct was not significant (n.s.) as analyzed by Student's t-test. (C). Identification of the minimal region in the TLR2 promoter (-60/
+110) necessary for basal TLR2 promoter activity. A series of 5' promoter deletion constructs were transiently transfected into HeLa cell to measure luci-
ferase activity. Luciferase activity is expressed as the percent activity of the pGL3-T2P (-309) plasmid. Results are presented as the mean ± S.E.M. from 
three independent experiments performed in triplicate.
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Assessment of SP1 binding site interactions with the adjacent CpG#18-20 site Figure 3
Assessment of SP1 binding site interactions with the adjacent CpG#18-20 site. (A) Mutation of the SP1 binding site within TLR2 promoter (-
120/+110) decreases basal TLR2 promoter activity in both non-CF and CF epithelial cells. The pGL3-T2P (-120), SP1 binding site-mutant pGL3-T2P (-120) 
SPm, pGL3-T2P (-12), or pGL3-null plasmids were each transiently transfected into HeLa cells. Luciferase activity is expressed as the percent activity of the 
pGL3-T2P (-120) construct. (B) Assessment of the effect of mutating the ETS binding site within the TLR2 -120/+110 promoter region. The pGL3-T2P (-
120), ETS binding site-mutant pGL3-T2P (-120) ETSm, pGL3-T2P (-12), or pGL3-null plasmids were each transiently transfected into HeLa cells. Luciferase 
activity is expressed as the percent activity of the pGL3-T2P (-120) construct. (C) Assessment of the effect of mutating the ETS binding site within TLR2 -
60/+110 promoter region. The pGL3-T2P (-60), mutant ETS binding site- pGL3-T2P (-60) ETSm construct, the pGL3-T2P (-12) construct, or the pGL3-
null plasmid were transiently transfected into HeLa cells. Luciferase activity is expressed as the percent activity of the pGL3-T2P (-60) construct. Data are 
presented as the mean ± S.E.M. from three independent experiments performed in triplicate. n.s. = not significant as assessed by Student's t test.
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Sp1-dependent regulation of hTLR2 promoter activity and TLR2 gene expression Figure 4
Sp1-dependent regulation of hTLR2 promoter activity and TLR2 gene expression. (A) Assessment of the effect of mithramycin A treatment on 
SP1-induced TLR2 promoter activation after co-transfecting HeLa cells with the pGL3-T2P (-120) or pGL3-null and with pcDNA3.1 empty vector the SP1 
or SP3 plasmids into HeLa cells. Cells were either untreated or treated 1 hr after transfection with 50 nM mithramycin A for 24 hr. Luciferase activity is 
expressed as the percent activity of the pGL3-T2P (-120) plasmid in pcDNA3.1-transfected, mitA-untreated cells. (B) Assessment of the effect of mutating 
the SP1 binding site within TLR2 -120/+110 promoter region. The pGL3-T2P (-120) or the pGL3-T2P (-120) SPm construct was co-transfected into HeLa 
cells with pcDNA3.1 or SP1 plasmid. The HeLa cells were also co-transfected with the pGL3-null and pcDNA3.1 plasmids as negative control. Luciferase 
activity is expressed as the percent activity of the pGL3-T2P (-120) construct in pcDNA3.1-co-transfected cells. Data are presented as the mean ± S.E.M. 
from 3 independent experiments performed in triplicate. *, p < 0.05; **, p < 0.0001 as assessed by ANOVA with Tukey-Kramer method. (C) SP1-depend-
ent TLR2 mRNA expression in human epithelial cells. CFBE41o- cells were either treated with mitA (0.5, 1, 5 μM) for 24 hr or untreated. Semi-quantita-
tive RT-PCR analysis was performed using the total RNA extracted from either CFBE41o- or 16HBE14o- cells. TLR2 expression was quantified by 
normalizing to GAPDH (control) and assayed using Image Gauge (top of the gel images). Results are representative of three independent experiments.
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SP1 and TLR2 expression
16HBE14o- cells were treated with 5-azacytidine (5-AC)
and mitA to assess if the endogenous methylation of DNA
affects SP1-induced TLR2 expression. Treatment with 5-
AC inhibited the methylation at CpG#18-20 (Fig. 6A, B)
and significantly increased TLR2 expression in
16HBE14o- cells (Fig. 6C) [17]. This 5-AC-induced
expression of TLR2 mRNA was inhibited by mitA (Fig.
6C). CAPE, a known inhibitor for NF-?B [19], had no
effect on 5-AC-mediated expression. Although 5-AC treat-
ment significantly increased the levels of TLR2 mRNA in
16HBE14o- cells, it did not affect endogenous SP1 expres-
sion (Fig. 6D). This indicates that 5-AC-induced up-regu-
lation of TLR2 mRNA in 16HBE14o- cells was due to the
increase of SP1-dependent transcriptional activity, but
independent of an increase in SP1 expression. Consistent
with this, notion is the observation that SP1 mRNA
expression (Fig. 7A), the nuclear expression of SP1 protein
(Fig. 7B), and SP1 binding to a TLR2 promoter probe (Fig.
7C) were all similar in these cells.
Methylation of CpG#18-20 and SP1 binding
The hypomethylation-dependent mechanisms underlying
TLR2 transcription were analyzed by EMSA using unmeth-
ylated and methylated probes. Oligonucleotide probes
methylated at one (mono) or three (tri) CpGs (Table 1,
T2P(-64/-31)-monoMe and T2P(-64/-31)-triMe, respec-
tively) were synthesized and subjected to EMSA analysis.
SP1 from 16HBE14o- cells binds to the unmethylated,
mono-methylated and tri-methylated probes (Fig. 8A,
lanes 2, 6, 10). SP1-specific binding was confirmed by the
supershift assay using an anti-SP1 antibody (Fig. 8A, lanes
4, 8, 12). Since the intensities of the bands from each reac-
tion were identical, it appears that methylation at
CpG#18-20 did not affect SP1 binding. Similar EMSA
band patterns were also observed using nuclear extracts
from CFBE41o- cells (Fig. 8B), suggesting that there is no
difference in SP1 binding in non-CF and CF epithelial
cells. These results indicate that mechanisms other than
differential SP1 binding in non-CF and CF epithelial cells
are responsible for the DNA methylation-dependent regu-
lation of TLR2 transcription in CF epithelial cells.
Discussion
In mammalian cells, CpG methylation in a promoter is a
primary epigenetic mechanism for silencing genes, and is
involved in the control of cellular function and homeos-
tasis. It is therefore reasonable to predict that aberrant
methylation of CpG regions within a promoter could
manifest in a pathology associated with some chronic dis-
eases. Recent studies have shown that TLR2 promoter
hypomethylation is associated with increased expression
of TLR2 in CF bronchial epithelial cells. This is consistent
with CF airway pathology that typically shows increased
proinflammatory responses to TLR2 bacterial ligands
[17]. The present study shows that a specific CpG region
of the TLR2 promoter, adjacent to an SP1 binding site, is
significantly demethylated, and that this promoter region
is both necessary and sufficient to maintain basal TLR2
promoter activity in human epithelial cells. These data
suggest that there are CFSMPs (CF-specific methylation
patterns) within TLR2 promoter, that might be used as
markers to facilitate the discovery of anti-inflammatory
CF drugs, as has been the case with anti-tumor drug dis-
covery [20,21].
The studies presented here also sought to clarify the
molecular mechanisms underlying demethylation-
dependent enhancement of TLR2 gene expression in CF
epithelial cells. SP1, but not SP3, appears to play a critical
role in maintaining basal TLR2 promoter activation in
human epithelial cells. Furthermore, SP1 appears to be
involved in regulating DNA demethylation-dependent
TLR2 transcriptional activity and expression. It is impor-
tant to note that the introduction of tri-methylation into
the promoter region adjacent to SP1 binding site did not
Inhibition of hTLR2 promoter activity by DNA methylation Figure 5
Inhibition of hTLR2 promoter activity by DNA meth-
ylation. SssI methylase-treated or untreated pGL3-T2P (-
120) was co-transfected into HeLa cells with the pcDNA3.1 
or the SP1 plasmid. HeLa cells were also co-transfected with 
pGL3-null and pcDNA3.1 as control. Luciferase activity is 
expressed as the percent activity of the pGL3-T2P (-120) 
plasmid in pcDNA3.1-co-transfected, methylase-untreated 
cells. Data are presented as the mean ± S.E.M. from three 
independent experiments performed in triplicate. *p < 
0.0001, assessed by Student's t-test.
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abrogate SP1 binding, and suggests that SP1 binding is
not rate limiting in regulating TLR2 mRNA expression.
Binding of some additional unknown "X" factors to the
tri-methylated probe, regardless of the source of nuclear
extract, was indicated in the EMSA assay (Fig. 8A, B, lanes
10 and 12, denoted by a sharp). This "X" factor band was
not observed in the non- or mono-methylated probes
(Fig. 8A, B, lanes 2, 4, 6 and 8), suggesting that the
increased methylation of CpG#18-20 in non-CF epithelial
cells enhances recruitment of factors that recognize tri-
methylated CpGs and suppress SP1-dependent transcrip-
tion without affecting the SP1 binding (Fig. 9, left panel).
Assessment of the effect of SP1 hypomethylation on TLR2 expression Figure 6
Assessment of the effect of SP1 hypomethylation on TLR2 expression. (A, B) 5-AC decreases CpG methylation adjacent to the SP1 binding site 
within human TLR2 promoter. Genomic DNA from 16HBE14o- cells was either treated with 5-AC for 7 days or untreated (n = 20 for 5-AC-untreated; n 
= 10 for 5-AC-treated) and then analyzed by sodium bisulfite sequencing. (A) Methylation profiles of the CpG sites (4, 5, 18, 19, 20) adjacent to the SP1 
binding sites within TLR2 promoter. (B) The percent of methylated CpGs in each CpG site is shown. (C) Assessment of the effect of Mit A treatment in 5-
AC-induced TLR2 up-regulation. 16HBE14o- cells were untreated or treated with 5-AC for 7 days, and then treated with mitA (0.1, 1 μM) for 24 hr or 
with 100 μM CAPE 3 hr. (D) SP1 expression after 5-AC treatment. 16HBE14o- and CFBE41o- cells were either treated with 5-AC for 7 days or 
untreated. Total RNA extracted from from both cell lines (in both (C) and (D)) and analyzed by semi-quantitative RT-PCR. TLR2 and SP1 expression was 
quantified by normalizing to GAPDH and assayed using Image Gauge. Results are representative of three independent experiments.
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SP1 expression in non-CF and CF epithelial cells Figure 7
SP1 expression in non-CF and CF epithelial cells. (A) SP1 mRNA expression in non-CF and CF epithelial cells. The levels 
of TLR2, SP1 and SP3 mRNA in the indicated cell lines were determined by semi-quantitative RT-PCR analysis. Gene expres-
sion was quantified by normalizing to GAPDH and assayed using Image Gauge. Results are representative of three independent 
experiments. (B) SP1 and SP3 protein levels in non-CF and CF epithelial cells were determined by Western blotting of nuclear 
extracts. Actin was used as an internal control. Results are representative of three independent experiments. (C) Sp1 binding 
in 16HBE14o- and CFBE41o- cells was assayed using labeled oligonucleotides containing the CpG#18-20 site and one putative 
Sp1 binding site (T2P(-64/-31)). Unlabeled WT oligonucleotides (lanes 3 and 8) or unlabeled mutant SP1 oligonucleotides 
(Table 1, T2P(-64/-31) SPm) (SP1 mt competitor, lanes 4 and 9) were added to the reaction solution for competition analysis. 
Supershift analysis was performed using an SP1 antibody (anti-SP1, lanes 5 and 10) to detect SP1-specific binding. Arrows indi-
cate SP1-containing complexes (SP1) and supershifted SP1 (SS).
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The effect of methylation on the binding of SP1 to CpG#18-20 Figure 8
The effect of methylation on the binding of SP1 to CpG#18-20. Labeled oligonucleotides containing unmethylated, sin-
gly-methylated, or triple-methylated CpG sites were mixed with nuclear extract derived from 16HBE14o- (A) or CFBE41o- (B) 
cells and subjected to EMSA. Competition analysis was carried out by adding unlabeled oligonucleotides (lanes 3, 7 and 11) to 
the reaction solution. Supershift analysis to detect SP1-specific binding was performed using an SP1 antibody (lanes 4, 8 and 
12). Arrows indicate the SP1-containing complexes (SP1) and the supershifted SP1 (SS). Bands derived from probes containing 
3 methylated CpGs are indicated by (#).
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On the other hand, the decreased methylation of
CpG#18-20, often observed in CF epithelial cells, might
abolish the recruitment and activity of these "X" factors,
and allowed SP1-dependent transcription of TLR2 (Fig. 9,
right panel).
The modulation of SP1 binding to its target sequences by
DNA methylation is controversial. In the promoters of
p21Cip1, 11-hydroxysteroid dehydrogenase type 2, and
GSTP1 (glutathione S-transferase p1), SP1 binding was
found to be diminished by DNA methylation [22-24]. In
contrast, SP1 binding to the claudin-4 (CLDN4) promoter
was not influenced by DNA methylation [25]. It was
found that the methyl-CpG-binding domain protein 2
(MBD2) was recruited to CpG sites and silenced the
CLDN4 gene in ovarian cancer cell lines without interfer-
ing with SP1 binding. The present study clearly indicates
that SP1 binding to a TLR2 promoter region was not
A potential model representing the mechanisms underlying hypomethylation-dependent TLR2 promoter activation in human  epithelial cells Figure 9
A potential model representing the mechanisms underlying hypomethylation-dependent TLR2 promoter acti-
vation in human epithelial cells. Enhanced methylation of the CpG#18-20 site within TLR2 promoter observed in non-CF 
epithelial cells is followed by the enhanced recruitment of unknown factors "X" that could recognize methylated CpGs and 
could suppress SP1-dependent transcriptional activation without affecting the binding of SP1 to those CpGs (left panel). 5-aza-
cytidine (5-AC) treatment of non-CF cells leads to the demethylation of CpG#18-20. On the other hand, CF epithelial cells 
express high level of TLR2 gene through decreased methylation of CpG#18-20, which might abolish the recruitment and activ-
ity of factors "X" in these cells (right panel).
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inhibited by DNA methylation. This is similar to what was
observed for the CLDN4 promoter [25]. Recruitment of
methyl binding proteins to the SP1 binding site in the
TLR2 promoter needs to be verified. MBD2 and/or the
methyl-CpG-binding protein 1 (MeCP1) complex, a large
protein complex that includes MBD2 [26], could be can-
didate "X" factors that interact with the methylated TLR2
promoter.
It is still unclear how the methylation patterns of the TLR2
promoter are determined in non-CF and CF epithelial cell
lines. Whether it is recruitment of factors required for
transcriptional activation or the recruitment of factors
required for silencing requires further study. The A549
and HeLa, cell lines used as non-CF epithelial cells in this
study, are not thought to express CFTR mRNA, yet their
TLR2 expression was comparable to that of the
16HBE14o- cells. Therefore, it appears that wt CFTR
expression may not be the only factor that would deter-
mine the TLR2 gene expression in epithelial cells. How-
ever, the processing of ?F508CFTR might affect the
transcription of the TLR2 gene through a mechanism that
involves the methylation of DNA and the expression of
specific transcriptional regulatory factors. Preliminary
studies comparing CF and non-CF cells showed no differ-
ence in the expressions of DNA methyl transferase genes,
DNmt1, DNmt3a, and DNmt3b [27,28], or in the DNA
demethylases, MBD2 and Gadd45a [27,29], (unpub-
lished data). One possible mechanism could involve the
recruitment of factors that releases the methylation-
induced transcription block by activating demethylation
of the promoter in the nucleus. Clearly, further investiga-
tion is required to elucidate these mechnaisms.
Conclusion
There appear to be CF-associated methylation patterns
within the human TLR2 (hTLR2) promoter, that lead to
increased expression of the TLR2 gene in CF epithelial
cells. Moreover, SP1-dependent transcription apppears to
be an important component of the molecular mecha-
nisms underlying CFSMPs-related aberrant regulation of
TLR2 expression in CF epithelial cells. Increased respon-
siveness to TLR2 ligands as well as an increase in TLR2
expression in CF epithelial cells have been proposed as a
contributing factor in CF-associated chronic inflamma-
tion. Therefore, CF-specific methylation patterns within
the TLR2 promoter may have important implications for
the development of therapies directed at sites regulating
TLR2 expression. Furthermore, the studies presented here
indicate that CF-specific hypomethylation of the hTLR2
promoter may influence regulation of other inflamma-
tion-associated genes that are aberrantly regulated in CF
epithelial cells [30-34]. Further study of this system may
provide insight into the molecular mechanisms regulating
inflammation in CF. This study underscores the role that
epigenetic mechanisms like DNA methylation play in the
modulation of gene expression in response to cellular
insult.
Methods
Reagents
5-azacytidine was purchased from Nacalai Tesque
(Japan). Mithramycin A was purchased from Sigma (St.
Louis, MO, USA). Caffeic acid phenethyl ester (CAPE) was
purchased from Calbiochem (Darmstadt, Germany).
Cell culture
16HBE14o- [35], CFBE41o- [36] and CFTE29o- [37] cells
were previously generated and grown in Fibronectin/Vit-
rogen/BSA-coated flask in MEM (Invitrogen, Carlsbard,
CA) [38]. CFPAC-1 cells [39] were purchased from ATCC
and grown in Iscove's modified Dulbecco's medium
(IMDM) (Invitrogen). The media were supplemented
with 10% fetal bovine serum (FBS), 100 mg/ml of penicil-
lin and 100 U/ml of streptomycin. The CFBE41o-,
CFTE29o- and CFPAC-1 cells were derived from CF
patients that are homozygous for the ?F508 CF transmem-
brane conductance regulator (?F508CFTR) mutation. The
non-CF epithelial cells in this study, 16HBE14o-, A549
and HeLa, were homozygous for wild type (wt)CFTR.
Expression of CFTR mRNA in A549 and HeLa cells has not
been confirmed.
Sodium bisulfite DNA Sequencing
Genomic DNA was isolated from various cell types using
the Blood and Cell Culture DNA Mini kit (Qiagen, Both-
ell, WA, USA) according to the manufacturer's protocol.
Sodium bisulfite DNA sequencing analysis of the TLR2
promoter has been previously described [17]. Briefly, PCR
products were subcloned into the pCR2.1-TOPO vector
(Invitrogen, Carlsbad, CA, USA), and > 10 clones from
each cell line were sequenced. The frequency of methyl-
ated CpG at each CpG site and the average % methylation
at each CpG site in the TLR2 proximal promoter were cal-
culated. The amount of methylated and unmethylated
DNA at each CpG site was compared in non-CF and CF
epithelial cells, and then statistically analyzed using
Fischer's exact test.
Plasmids
Full-length human TLR2 (hTLR2) promoter constructs,
were generated by amplifying different lengths up to 309-
bp 5' of the TLR2 gene coding region using genomic DNA
prepared from A549 cells as the template for High Fidelity
AccuPrime™ Taq DNA Polymerase (Invitrogen). The PCR
primers used in the amplification are indicated in Table 1.
The PCR products generated were cloned into pCR2.1-
TOPO vector using the TOPO-TA cloning kit (Invitrogen).
The TLR2 promoter-luc reporter construct was generated
by subcloning the TLR2 promoter fragment into the XhoI-BMC Molecular Biology 2008, 9:39 http://www.biomedcentral.com/1471-2199/9/39
Page 14 of 15
(page number not for citation purposes)
HindIII sites of the pGL3-Basic vector (Promega, Madison,
WI, USA). Mutant TLR2 promoter constructs were gener-
ated utilizing the QuikChange II site-directed mutagenesis
kit from Stratagene (La Jolla, CA, USA) according to the
manufacturer's instructions. The oligonucleotide primers
used to generate the mutants are shown in Table 1.
Mutant constructs were generated using either the pGL3-
T2P(-120) or the pGL3-T2P(-60) construct as template.
The pGL3-T2P(-120) plasmid was either methylated or
mock-methylated in the presence or absence, respectively,
of SssI methylase. Construct methylation was confirmed
by digestion with methylation-dependent HapII and
methylation-independent  MspI enzymes. The TLR2
expression plasmid and the luciferase reporter construct,
IL-8-luc, were described previously [40]. The NF-?B-luc
construct was purchased from Stratagene (La Jolla, CA,
USA). Expression plasmids for SP1 and SP3 were kindly
provided by Dr. G. Suske [41]. Plasmid constructs used in
this study were sequenced with ABI3730XL DNA
sequencer at the genomics facility of Macrogen (Seoul,
South Korea).
Transient transfection and luciferase assay
Transient transfections with the pGL3-T2P plasmids, NF-
?B-luc and IL-8-luc reporter constructs were carried out
using the TransIT-LT1 transfection reagent (Panvera, Mad-
ison, WI, USA) as previously described [19]. In brief, sub-
confluent cells in 12-well plates were transfected with 0.4
µg reporter plasmid and 10 ng of the Renilla luciferase vec-
tor (phRG-TK; Promega). The empty pcDNA3.1 vector
was used as a control for the TLR2 and SP1/3 transfection
experiments. After 48 hrs, the transfected and control cells
were harvested and luciferase activity was measured by the
Dual-Luciferase Reporter Assay system (Promega) in a
luminometer. Relative luciferase activity is presented as %
activity of each control described in each figure legend.
Values shown are the mean ± S.E.M. (n = 3).
Semi-quantitative RT-PCR analysis
Total RNA from human epithelial cells was isolated using
ISOGEN (NIPPONGENE, Tokyo, Japan) according to the
manufacturer's instruction. Semi-quantitative RT-PCR
was carried out using the RNA-PCR Kit (TaKaRa, Tokyo,
Japan). PCR amplifications of TLR2 and GAPDH was per-
formed as previously described [42]. The amplification
conditions for SP1 and SP3 are as follows: 94°C for 60 s,
60°C for 60 s, and 72°C for 60 s (for 24 cycles). The oli-
gonucleotide primers used in the PCR amplifications are
as indicated (Table 1). Quantitative analyses were per-
formed by using Image Gauge (FUJI FILM, Tokyo, Japan).
Western blotting
SP1 and SP3 protein expression was assayed as previously
described [18]. Equal amounts of nuclear protein extract
(30 µg) were fractionated by 8% SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluo-
ride membrane (Millipore, Bedford, MA, USA). The mem-
brane was blocked with PBS-T (PBS, 0.1% (v/v) Tween
20) and 5% nonfat milk. Detection of SP1 and SP3 with
anti-SP1 and anti-SP3 rabbit polyclonal antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was carried as
described [18]. Actin expression was determined using a
goat anti-actin polyclonal antibody (Santa Cruz Biotech-
nology) as the internal control.
Electrophoresis mobility shift assay (EMSA)
EMSA was performed as described [18]. Briefly, nuclear
extracts (7.5 µg) from 16HBE14o- and CFBE41o- cells
were incubated with [?-32P]-labeled oligonucleotides rep-
resenting TLR2 promoter region -64/-31 with or without
the indicated excess of unlabeled competitors. The DNA-
protein complexes were resolved in 4.5% polyacrylamide
gels. The SP1 antibody (4 µg) was used for supershift
assays, and the migrating bands were visualized autoradi-
ographically using BAS-2000 (Fuji film, Japan). The oligo-
nucleotides used in the EMSA are as indicated (Table 1).
Statistical analysis
Statistical analysis of luciferase activity was performed by
one-way ANOVA with either Tukey-Kramer or Dunnett's
multiple comparison test (JMP software, SAS Institute,
NC, USA) as indicated in each figure legends. Statistical
analysis of methylation (Tables 2 and 3) was performed
by the Fischer's exact test to assign p values.
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